PFS according to response after 2 cycles of Vel-Dex therapy and pretreatment of two ALC groups. Patients achieving CR and VGPR have longer PFS than those achieving PR or SD (p < 0.001, p < 0.001, respectively) and patients achieving PR have longer PFS than those achieving SD (p = 0.009), while PFS in patients achieving CR was not significantly different from PFS in those achieving VGPR (p = 0.194). PFS in the high-ALC group before Vel-Dex therapy was longer than in the low-ALC group (p < 0.001).